Partnering Opportunities In Cardio/Metabolics: “Everybody’s Looking And Nobody’s Got”
This article was originally published in The Pink Sheet Daily
Representatives from J&J, GSK, Pfizer and Boehringer Ingelheim discuss their companies’ thinking in terms of cardiovascular/metabolic drug development and business development activity at the TAP conference.
You may also be interested in...
Boehringer Ingelheim GMBH and Eli Lilly & Co. are likely to play up simplicity of dosing for the just-approved DPP-4 inhibitor Tradjenta (linagliptin) in a launch planned for the end of May, and expect to price the drug on par with others in the class.
Boehringer Ingelheim GmbH's breakthrough anticoagulant Pradaxa (dabigatran) will be available to physicians and patients in the "next several days," the company said after FDA cleared the drug Oct. 19.